CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Karo Pharma AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Karo Pharma AB
Klara Norra Kyrkogata 33
Phone: +46 84443820p:+46 84443820 STOCKHOLM, 111 22  Sweden Ticker: 0RAQ0RAQ

This company was Merged or Acquired on 9/20/2022.
This is a Subsidiary, click here for the Parent Company

Business Summary
Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer treatment; ERbeta multiple sclerosis (MS), which specializes in the autoimmune disease MS treatment; and Related Orphan Receptor Gamma (RORgamma), which is responsible for the nuclear receptors application in treatment of autoimmune disease, such as rheumatoid arthritis and psoriasis. The Company collaborates with Pfizer, 4D Science, and Merck, among others. Its trademarks portfolio includes Karo Bio, BioKey, BioKey Assay and Molecular Braille. The Company operates Karo Bio Research AB, Karo Bio Discovery AB, Kommanditbolaget Odenplan Fastigheter, Tanomed AB, MedCore AB and Medireduce AB as subsidiaries.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202212/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board PatrickSmallcombe 59 4/21/2021 4/21/2021
Chief Executive Officer ChristofferLorenzen 46 7/1/2019 2/14/2019
Chief Financial Officer JonJohnsson 47 10/1/2019 10/1/2019
12 additional Officers and Directors records available in full report.

Business Names
Business Name
0RAQ
BioPhausia AB
Cederroth A/S
9 additional Business Names available in full report.

General Information
Number of Employees: 242 (As of 12/31/2021)
Outstanding Shares: 273,254,604 (As of 6/30/2022)
Shareholders: 7,003
Stock Exchange: STO
Fax Number: +46 87748261


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024